FDA granted a Rare Pediatric Disease Designation to ABT-414, an investigational antibody drug conjugate targeting the epidermal growth factor receptor for the treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Glioma, known to be highly aggressive and difficult to treat brain tumors found at the base of the brain. According to AbbVie, the drug’s...
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe